BTK Inhibitor
Bruton's Tyrosine Kinase Inhibitor (CNS-Penetrant B-Cell & Microglial Modulator)
BTK阻害薬（脳移行性ブルトン型チロシンキナーゼ阻害薬：B細胞・ミクログリア二重標的）
1. Biological & Technical Mechanism
Bruton's tyrosine kinase (BTK) is an intracellular non-receptor tyrosine kinase essential for B-cell receptor (BCR) antigen-presentation/maturation in B lymphocytes and Fc-gamma receptor (FcγR) / Toll-like receptor signaling in myeloid cells (microglia and macrophages). Unlike large anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab) that deplete peripheral B cells but have <0.1% blood-brain barrier penetration, small-molecule CNS-penetrant BTK inhibitors (such as tolebrutinib, fenebrutinib, and remibrutinib) reach therapeutic concentrations inside the brain parenchyma and leptomeninges to directly modulate iron-laden MIMS microglia at the rim of chronic active lesions.
ブルトン型チロシンキナーゼ（BTK）は、Bリンパ球におけるB細胞受容体（BCR）下流の活性化・抗原提示シグナルと、ミクログリアやマクロファージにおけるFcγ受容体（FcγR）介在性の炎症シグナルの両方を制御する細胞内キナーゼです。既存の抗CD20モノクローナル抗体（オクレリズマブ、オファツムマブ等）は末梢血中のB細胞を強力に枯渇させて急性再発を防ぐ一方、分子量が大きいため血液脳関門（BBB）をほ��んど通過できません。これに対し、低分子化合物である脳移行性BTK阻害薬（Tolebrutinib、Fenebrutinib、Remibrutinib等）は脳実質および軟髄膜へ直接移行し、B細胞の機能抑制に加えて常磁性リム病変（PRL）辺縁の活性化ミクログリアを直接鎮静化することで、非再発性の二次性進行型MS（nrSPMS）におけるPIRA抑制効果を示しています。
2. Open Science & Clinical Trial Significance
Phase 3 clinical trials (e.g., HERCULES, GEMINI, PERSEUS, FENhance) and single-cell microglial transcriptomic benchmarks evaluate BTK inhibition on 6-month CDA, PRL resolution, and brain volume loss.
進行型MSに対する第3相試験（HERCULES試験等）の主要評価項目達成により、PIRAおよび慢性活動性ミクログリア（MIMS）を標的とする中枢神経系創薬の最重要モダリティとして注目されています。
Related Neuroscience Terms & Standards
Irreversible accumulation of neurological disability occurring outside of clinical relapses, driven by diffuse smoldering neuroinflammation, chronic active lesions, and neuroaxonal loss in MS.
Chronic white matter MS lesions bordered by a dense rim of iron-laden, proinflammatory activated microglia/macrophages, visible on T2* phase MRI, SWI, and QSM.
Standard 0.0–10.0 ordinal clinical rating scale quantifying neurological disability across 8 functional systems and ambulation capacity in Multiple Sclerosis.
Latent B-cell-tropic herpesvirus established as the leading causal environmental trigger of Multiple Sclerosis (~32-fold risk increase), driving CNS autoimmunity via EBNA1 molecular mimicry.
High-throughput transcriptomic profiling at individual cell or nucleus resolution, enabling identification of disease-associated microglia (DAM), astrocytes, and vulnerable neuronal subtypes.
Open Datasets & Research Publications Related to BTK Inhibitor
MSDA: COVID19 GDSI LocalDashboard - Federated MS Data Toolkit
Official open-source repository and tool for Multiple Sclerosis federated research and data harmonization under MS-DATA-ALLIANCE.
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data.
CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
BackgroundCNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. ObjectivesTo evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results...
Dietary Patterns and Nutritional Factors in Multiple Sclerosis: A Narrative Review
Research article from Europe PMC.
MSDA Core Dataset (CDS): Standardized Global Real-World Data Harmonization Framework for Multiple Sclerosis
The MSDA Core Dataset (CDS) establishes a 44-variable international harmonization schema mapped to the OMOP Common Data Model, enabling privacy-preserving federated analytics across global Multiple Sclerosis registries.
MSDA Global Registry & Cohort Metadata Discovery Catalogue (BigMS Network)
A centralized metadata discovery catalogue indexing over 30 national and international MS registries (>120,000 patients), detailing variable availability for EDSS, relapse history, MRI, fluid biomarkers, and DUA governance.
Disclaimer: This encyclopedia entry is intended for academic neuroscience research and data science reference only, and does not constitute medical advice.